MX2020009978A - Proceso y sistema para obtener neurotoxina botulinica. - Google Patents

Proceso y sistema para obtener neurotoxina botulinica.

Info

Publication number
MX2020009978A
MX2020009978A MX2020009978A MX2020009978A MX2020009978A MX 2020009978 A MX2020009978 A MX 2020009978A MX 2020009978 A MX2020009978 A MX 2020009978A MX 2020009978 A MX2020009978 A MX 2020009978A MX 2020009978 A MX2020009978 A MX 2020009978A
Authority
MX
Mexico
Prior art keywords
botulinum neurotoxin
obtain botulinum
cosmetic
therapeutic
systems
Prior art date
Application number
MX2020009978A
Other languages
English (en)
Inventor
Jennifer L Ton
Hemant A Patel
Ronald C Bates
Wajdie M Ahmad
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42537891&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2020009978(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of MX2020009978A publication Critical patent/MX2020009978A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction, e.g. ion-exchange, ion-pair, ion-suppression or ion-exclusion
    • B01D15/361—Ion-exchange
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction, e.g. ion-exchange, ion-pair, ion-suppression or ion-exclusion
    • B01D15/361—Ion-exchange
    • B01D15/362—Cation-exchange
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction, e.g. ion-exchange, ion-pair, ion-suppression or ion-exclusion
    • B01D15/361—Ion-exchange
    • B01D15/363—Anion-exchange
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/145—Clostridium
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24069—Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Birds (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Procesos y sistemas cromatográficos rápidos, libres de proteína animal para obtener neurotoxina botulínica con alto rendimiento y alta potencia, para uso terapéutico, cosmético y en la investigación.
MX2020009978A 2009-07-13 2012-01-12 Proceso y sistema para obtener neurotoxina botulinica. MX2020009978A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US12/502,181 US8129139B2 (en) 2009-07-13 2009-07-13 Process for obtaining botulinum neurotoxin

Publications (1)

Publication Number Publication Date
MX2020009978A true MX2020009978A (es) 2020-10-12

Family

ID=42537891

Family Applications (4)

Application Number Title Priority Date Filing Date
MX2012000615A MX2012000615A (es) 2009-07-13 2010-07-12 Proceso y sistema para obtener neurotoxina botulinica.
MX2016009206A MX375629B (es) 2009-07-13 2010-07-12 Proceso y sistema para obtener neurotoxina botulínica.
MX2014008854A MX340718B (es) 2009-07-13 2010-07-12 Proceso y sistema para obtener neurotoxina botulinica.
MX2020009978A MX2020009978A (es) 2009-07-13 2012-01-12 Proceso y sistema para obtener neurotoxina botulinica.

Family Applications Before (3)

Application Number Title Priority Date Filing Date
MX2012000615A MX2012000615A (es) 2009-07-13 2010-07-12 Proceso y sistema para obtener neurotoxina botulinica.
MX2016009206A MX375629B (es) 2009-07-13 2010-07-12 Proceso y sistema para obtener neurotoxina botulínica.
MX2014008854A MX340718B (es) 2009-07-13 2010-07-12 Proceso y sistema para obtener neurotoxina botulinica.

Country Status (18)

Country Link
US (19) US8129139B2 (es)
EP (6) EP3252070B1 (es)
JP (6) JP5887268B2 (es)
KR (5) KR101916139B1 (es)
CN (2) CN106117325B (es)
BR (1) BR112012000784A2 (es)
CA (1) CA2767760C (es)
CY (2) CY1119519T1 (es)
DK (2) DK3252070T3 (es)
ES (2) ES2770031T3 (es)
HU (2) HUE033888T2 (es)
IN (1) IN2012DN00456A (es)
MX (4) MX2012000615A (es)
PL (2) PL3252070T3 (es)
PT (2) PT2454275T (es)
RU (1) RU2561459C2 (es)
SI (2) SI3252070T1 (es)
WO (1) WO2011008713A1 (es)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8632785B2 (en) * 2000-02-08 2014-01-21 Allergan, Inc. Clostridial toxin pharmaceutical composition containing a gelatin fragment
ES2509872T3 (es) 2005-03-03 2014-10-20 Allergan, Inc. Procedimientos para obtener una toxina clostrídica
US8168206B1 (en) 2005-10-06 2012-05-01 Allergan, Inc. Animal protein-free pharmaceutical compositions
US8129139B2 (en) * 2009-07-13 2012-03-06 Allergan, Inc. Process for obtaining botulinum neurotoxin
SI2490986T1 (sl) 2009-10-21 2018-12-31 Revance Therapeutics, Inc. Metode in sistemi za prečiščenje nekompleksiranega nevrotoksina botulina
KR20110046178A (ko) * 2009-10-28 2011-05-04 엘지전자 주식회사 이동 단말기
KR101134146B1 (ko) 2010-05-31 2012-04-19 메덱스젠 주식회사 국소 근마비 효과를 갖는 비확산형 보툴리눔 독소와 그의 정제방법
US9605887B2 (en) 2011-07-29 2017-03-28 Hdt Expeditionary Systems, Inc. Transportable packaged ice supply system for high temperature environments
GB201113544D0 (en) * 2011-08-05 2011-09-21 Fujifilm Diosynth Biotechnologies Uk Ltd Purification process
WO2014197837A1 (en) * 2013-06-06 2014-12-11 University Of Florida Research Foundation, Inc. Materials and methods for producing a biological toxin
HK1225744A1 (zh) 2013-07-30 2017-09-15 Merz Pharma Gmbh & Co. Kgaa 制备高纯度的肉毒杆菌毒素神经毒性组分的方法及其应用
KR101339349B1 (ko) * 2013-08-02 2013-12-09 주식회사 대웅 보툴리눔 독소의 제조방법
JP6373376B2 (ja) * 2013-11-15 2018-08-15 ノバルティス アーゲー 残留細胞培養不純物の除去
US9480731B2 (en) * 2013-12-12 2016-11-01 Medy-Tox, Inc. Long lasting effect of new botulinum toxin formulations
GB201407525D0 (en) * 2014-04-29 2014-06-11 Syntaxin Ltd Manufacture of recombinant clostridium botulinum neurotoxins
KR101729251B1 (ko) * 2015-04-28 2017-04-21 주식회사 대웅 보툴리눔 독소의 제조를 위한 배지 조성물
GB201517450D0 (en) * 2015-10-02 2015-11-18 Ipsen Biopharm Ltd Method
KR101775682B1 (ko) * 2015-11-30 2017-09-06 주식회사 대웅 보툴리눔 독소의 제조방법
WO2017161345A1 (en) 2016-03-18 2017-09-21 Biomadison, Inc. Improved cell based assay
KR102480965B1 (ko) 2016-09-13 2022-12-26 알레간 인코포레이티드 안정화된 비단백질 클로스트리듐 독소 조성물
KR102463881B1 (ko) * 2016-10-04 2022-11-07 (주)메디톡스 보툴리눔 독소 함유 용액으로부터 보툴리눔 독소를 분리하는 방법
EP3600221A4 (en) * 2017-03-22 2021-01-13 Bonti, Inc. BOTULINARY NEUROTOXINS FOR USE IN THERAPY
CA3060669A1 (en) * 2017-04-28 2018-11-01 Bonti, Inc. Botulinum neurotoxins production methods
CA3068292A1 (en) * 2017-06-26 2019-01-03 Bonti, Inc. Clostridial neurotoxin formulations and use
KR102140531B1 (ko) * 2018-08-07 2020-08-04 (주)휴온스 Gly-Tβ4의 제조방법
US11926853B2 (en) 2018-12-21 2024-03-12 The Research Foundation For Microbial Diseases Of Osaka University Botulinum toxin producing method
KR102209159B1 (ko) 2019-03-29 2021-01-29 (주)제테마 독소의 제조방법
KR102197224B1 (ko) 2019-03-29 2020-12-31 (주)제테마 배지 조성물
KR102516203B1 (ko) * 2019-04-15 2023-03-30 (주)제테마 보툴리눔 독소의 제조방법
KR102485146B1 (ko) * 2019-04-15 2023-01-06 (주)제테마 보툴리눔 독소의 제조방법
US10851363B1 (en) 2019-05-22 2020-12-01 Boke Zhang Multilayer nano-cell containing biomolecules
KR102287437B1 (ko) * 2019-08-14 2021-08-09 주식회사 프로톡스 보툴리눔 독소의 제조방법
TWI854077B (zh) * 2019-12-20 2024-09-01 瑞士商葛德瑪控股公司 生產肉毒桿菌毒素的方法
TW202136286A (zh) * 2019-12-20 2021-10-01 瑞士商葛德瑪控股公司 純化肉毒桿菌毒素的方法
CN114958887B (zh) * 2021-02-26 2024-10-25 重庆誉颜制药有限公司 一种经修饰的毒素多肽的制备方法
KR102724651B1 (ko) * 2021-07-08 2024-11-01 주식회사 파마리서치바이오 비-독소 단백질이 제거된 클로스트리디움 보툴리눔 신경독소 단백질의 정제방법
KR102427362B1 (ko) * 2021-11-11 2022-08-01 (주)이니바이오 보툴리눔 독소 제제의 건조 공정
KR102850152B1 (ko) * 2022-07-27 2025-08-25 (주)이니바이오 감압건조장치 및 이를 이용한 감압건조방법
EP4615489A1 (en) 2022-11-07 2025-09-17 Allergan, Inc. Prevention of post-operative atrial fibrillation with a botulinum toxin
CH720444A2 (de) 2023-01-20 2024-07-31 Abbvie Inc Clostridium botulinum serotyp a neurotoxin (bont/a)- sequenzvarianten
CH720447A2 (de) 2023-01-20 2024-07-31 Abbvie Inc Zusammensetzungen von clostridium botulinum neurotoxin serotyp a
WO2025111258A1 (en) * 2023-11-20 2025-05-30 Abbvie Inc. Clostridium botulinum neurotoxin serotype a compositions and improved filtration processes
DE102025101336A1 (de) 2024-01-19 2025-07-24 Abbvie Inc. Zusammensetzungen von clostridium botulinum neurotoxin serotyp a und verbesserte trocknungsprozesse

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4401683A (en) 1981-07-06 1983-08-30 Fmc Corporation Carbohydrate food products resistant to Clostridium botulinum and the formation of enterotoxin
WO1994000481A1 (en) 1992-06-23 1994-01-06 Associated Synapse Biologics Pharmaceutical composition containing botulinum b complex
TW257792B (es) * 1992-10-01 1995-09-21 Lilly Co Eli
JP3265577B2 (ja) 1992-10-13 2002-03-11 デューク・ユニバーシティ アポリポ蛋白ｅの４型イソ型の測定法
US5314822A (en) 1992-10-15 1994-05-24 Merck & Co., Inc. Method of clonal growth of Streptococcus pneumoniae
US5962637A (en) 1994-06-03 1999-10-05 Microbiological Research Authority Toxin assay
GB9411138D0 (en) 1994-06-03 1994-07-27 Microbiological Res Authority Toxin assay
AU2907695A (en) 1994-08-08 1996-03-07 Wisconsin Alumni Research Foundation Purification and pharmaceutical compositions containing type g botulinum neurotoxin
US5756468A (en) 1994-10-13 1998-05-26 Wisconsin Alumni Research Foundation Pharmaceutical compositions of botulinum toxin or botulinum neurotoxin and methods of preparation
US5512547A (en) 1994-10-13 1996-04-30 Wisconsin Alumni Research Foundation Pharmaceutical composition of botulinum neurotoxin and method of preparation
EP0773788B1 (en) 1995-06-06 2003-05-07 L. Bruce Pearce Improved compositions and methods for chemodenervation using neurotoxins
US6444209B1 (en) 1996-10-28 2002-09-03 Wisconsin Alumni Research Foundation Hybrid botulinal neurotoxins
DE69838383T2 (de) 1997-05-28 2008-06-05 Novartis Vaccines And Diagnostics S.R.L. Kulturmedium mit sojabohnenextrakt als aminosäuren-quelle und ohne proteinkomplexe tierischen ursprungs
JP4055248B2 (ja) * 1998-05-25 2008-03-05 味の素株式会社 精製ヒトアクチビン及びその製造方法
GB9902000D0 (en) 1999-01-30 1999-03-17 Delta Biotechnology Ltd Process
DE19925739A1 (de) 1999-06-07 2000-12-21 Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh Therapeutikum mit einem Botulinum-Neurotoxin
US6558926B1 (en) 1999-07-16 2003-05-06 Massachusetts Institute Of Technology Method for production of tetanus toxin using media substantially free of animal products
WO2001036655A2 (en) 1999-11-12 2001-05-25 Eli Lilly And Company Method for optimization of a medium for glycopeptide fermentation
AU1486801A (en) 1999-11-15 2001-05-30 Curagen Corporation Novel growth factor polypeptides and nucleic acids encoding same
DE10004024A1 (de) 2000-01-31 2001-08-02 Guenther Bebenroth Schaltungsanordnung zum Betreiben von Leuchtdioden
DK1398038T4 (da) 2000-02-08 2011-03-28 Allergan Inc Lægemidler med botulinustoxin
US20030118598A1 (en) 2000-02-08 2003-06-26 Allergan, Inc. Clostridial toxin pharmaceutical compositions
US20060269575A1 (en) * 2000-02-08 2006-11-30 Allergan, Inc. Botulinum toxin pharmaceutical compositions formulated with recombinant albumin
US8632785B2 (en) 2000-02-08 2014-01-21 Allergan, Inc. Clostridial toxin pharmaceutical composition containing a gelatin fragment
US6811067B2 (en) 2000-02-10 2004-11-02 Magna International Inc. Vehicle tailgate with storage capacity
JP2003009897A (ja) 2001-07-03 2003-01-14 Keiji Oguma ボツリヌス毒素の分離・精製法
CA2456843A1 (en) 2001-08-14 2003-02-27 Statens Serum Institut A purification process for large scale production of gc-globulin, product obtained thereby and their use in medicine
US7208285B2 (en) 2001-08-28 2007-04-24 Allergan, Inc. Fret protease assays for botulinum serotype A/E toxins
US8022172B2 (en) 2001-08-28 2011-09-20 Allergan, Inc. Luminescence resonance energy transfer (LRET) assays for clostridial toxin activity
US7332567B2 (en) 2001-08-28 2008-02-19 Allergan, Inc. Fret protease assays for clostridial toxins
KR20030060150A (ko) 2002-01-07 2003-07-16 (주)메디톡스 클로스트리디움 보툴리눔 ａ형 독소를 정제하는 방법
RU2230325C2 (ru) * 2002-08-15 2004-06-10 Научно-исследовательский институт микробиологии Министерства обороны Российской Федерации Способ приготовления очищенного препарата ботулинического токсина типа а
US7183066B2 (en) 2002-09-27 2007-02-27 Allergan, Inc. Cell-based fluorescence resonance energy transfer (FRET) assays for clostridial toxins
US20040235139A1 (en) 2002-12-23 2004-11-25 Demain Arnold L. Clostridium difficile culture and toxin production methods
EP1493478B1 (en) * 2003-07-02 2007-04-04 Filtertek Inc. Multiple bridge retainer
US7160699B2 (en) 2003-09-25 2007-01-09 Allergan, Inc. Media for clostridium bacterium and processes for obtaining a clostridial toxin
US7148041B2 (en) 2003-09-25 2006-12-12 Allergan, Inc. Animal product free media and processes for obtaining a botulinum toxin
US7452697B2 (en) 2003-09-25 2008-11-18 Allergan, Inc. Chromatographic method and system for purifying a botulinum toxin
US20070264373A1 (en) 2004-01-26 2007-11-15 Ian Carroll Toxin Induced Sympathectomy
ES2374822T3 (es) 2004-02-24 2012-02-22 Allergan, Inc. Ensayo de selección de toxinas botul�?nicas.
EP2266599B1 (en) 2004-07-26 2014-04-16 Merz Pharma GmbH & Co. KGaA Therapeutic composition with a botulinum neurotoxin
US20060069562A1 (en) 2004-09-10 2006-03-30 Adams Marilyn J Word categories
US7399607B2 (en) 2004-09-22 2008-07-15 Allergan, Inc. Fluorescence polarization assays for determining clostridial toxin activity
US20070258992A1 (en) 2004-10-06 2007-11-08 Atassi M Zouhair Determining and Reducing Immunoresistance to Botulinum Toxin Therapy Using Botulinum Toxin a Peptides
US20070277577A1 (en) 2004-10-29 2007-12-06 Allen Clyde G Sheet metal brake and hinge mechanism therefor
EP2360171A1 (en) * 2004-12-23 2011-08-24 Novo Nordisk Health Care AG Reduction of the content of protein contaminants in compositions comprising a vitamin K-dependent protein of interest
ES2509872T3 (es) 2005-03-03 2014-10-20 Allergan, Inc. Procedimientos para obtener una toxina clostrídica
EP2293064B1 (en) 2005-04-05 2012-04-04 Allergan, Inc. Lipophilic dye-based FRET assays for clostridial toxin activity
US8323666B2 (en) 2005-08-01 2012-12-04 Allergan, Inc. Botulinum toxin compositions
US7744904B1 (en) 2005-09-26 2010-06-29 B.B. Scientific L.L.C. Stabilization of Clostridium botulinum neurotoxin complex
CN103126971A (zh) 2005-11-17 2013-06-05 雷文斯治疗公司 减少非毒素蛋白质的肉毒杆菌毒素组合物和其局部施用及透皮递送方法
PT2271670E (pt) 2008-03-14 2014-11-28 Allergan Inc Ensaio imunobaseado da atividade do serotipo a da toxina botulínica
KR20090120222A (ko) 2008-05-19 2009-11-24 (주)메디톡스 식물 유래 성분 함유 배지 및 가요성 폐쇄 용기를 이용하여클로스트리디움 보툴리눔 독소를 생산하는 방법
KR101923847B1 (ko) 2009-03-13 2018-11-29 알러간, 인코포레이티드 면역 기반 재표적화된 엔도펩티다제 활성 검정
US8129139B2 (en) * 2009-07-13 2012-03-06 Allergan, Inc. Process for obtaining botulinum neurotoxin
SI2490986T1 (sl) 2009-10-21 2018-12-31 Revance Therapeutics, Inc. Metode in sistemi za prečiščenje nekompleksiranega nevrotoksina botulina
NL2010545C2 (en) 2013-03-28 2014-09-30 Ihc Holland Ie Bv Skidding system for an offshore installation or vessel.
KR101339349B1 (ko) 2013-08-02 2013-12-09 주식회사 대웅 보툴리눔 독소의 제조방법
US9889608B2 (en) 2014-11-10 2018-02-13 International Business Machines Corporation Matching the scale of independent objects or intelligently scaling objects when 3D printing
KR101723167B1 (ko) 2015-04-28 2017-04-05 주식회사 대웅 보툴리눔 독소의 제조를 위한 배지 조성물
KR101775682B1 (ko) 2015-11-30 2017-09-06 주식회사 대웅 보툴리눔 독소의 제조방법
KR102463881B1 (ko) 2016-10-04 2022-11-07 (주)메디톡스 보툴리눔 독소 함유 용액으로부터 보툴리눔 독소를 분리하는 방법

Also Published As

Publication number Publication date
CN106117325B (zh) 2021-08-10
EP4299070A2 (en) 2024-01-03
US11326155B2 (en) 2022-05-10
US11530400B2 (en) 2022-12-20
US20220228136A1 (en) 2022-07-21
US20200071686A1 (en) 2020-03-05
PT3252070T (pt) 2020-01-14
US20220204958A1 (en) 2022-06-30
US8129139B2 (en) 2012-03-06
US20170327811A1 (en) 2017-11-16
WO2011008713A1 (en) 2011-01-20
US11518986B2 (en) 2022-12-06
DK3252070T3 (da) 2020-01-20
SI2454275T1 (sl) 2017-12-29
US20150184141A1 (en) 2015-07-02
MX2012000615A (es) 2012-03-26
CY1122567T1 (el) 2021-01-27
EP3252070B1 (en) 2019-10-02
CN102482332B (zh) 2016-08-03
KR20170019489A (ko) 2017-02-21
US20120245324A1 (en) 2012-09-27
EP3252070A1 (en) 2017-12-06
US8324349B2 (en) 2012-12-04
RU2012104778A (ru) 2013-08-20
KR101667174B1 (ko) 2016-10-17
RU2561459C2 (ru) 2015-08-27
JP2024111147A (ja) 2024-08-16
JP2020078306A (ja) 2020-05-28
EP4699614A2 (en) 2026-02-25
EP2454275B1 (en) 2017-07-12
ES2770031T3 (es) 2020-06-30
US9206409B2 (en) 2015-12-08
CN106117325A (zh) 2016-11-16
IN2012DN00456A (es) 2015-05-15
KR101784532B1 (ko) 2017-10-11
US20230123158A1 (en) 2023-04-20
EP2454275A1 (en) 2012-05-23
JP2012532932A (ja) 2012-12-20
KR20120105417A (ko) 2012-09-25
US20160097045A1 (en) 2016-04-07
MX340718B (es) 2016-07-22
PT2454275T (pt) 2017-10-23
KR101916139B1 (ko) 2018-11-08
CN102482332A (zh) 2012-05-30
US20220033796A1 (en) 2022-02-03
KR20150085140A (ko) 2015-07-22
US20120123095A1 (en) 2012-05-17
EP4141024A1 (en) 2023-03-01
DK2454275T3 (en) 2017-10-23
JP6356651B2 (ja) 2018-07-11
KR20190111161A (ko) 2019-10-01
US10465178B2 (en) 2019-11-05
HUE047362T2 (hu) 2020-04-28
JP6704329B2 (ja) 2020-06-03
EP3640259A1 (en) 2020-04-22
US20220251532A1 (en) 2022-08-11
US20210292727A1 (en) 2021-09-23
CA2767760A1 (en) 2011-01-20
HUE033888T2 (en) 2018-01-29
PL2454275T3 (pl) 2017-12-29
ES2643554T3 (es) 2017-11-23
US20110008843A1 (en) 2011-01-13
US11124786B2 (en) 2021-09-21
US8932827B2 (en) 2015-01-13
US20220298496A1 (en) 2022-09-22
SI3252070T1 (sl) 2020-03-31
KR20180122039A (ko) 2018-11-09
US8927229B2 (en) 2015-01-06
US9719076B2 (en) 2017-08-01
EP4299070A3 (en) 2024-03-27
US20230021648A1 (en) 2023-01-26
PL3252070T3 (pl) 2020-04-30
MX375629B (es) 2025-03-06
US20220145279A1 (en) 2022-05-12
US20120156756A1 (en) 2012-06-21
JP2016028601A (ja) 2016-03-03
JP5887268B2 (ja) 2016-03-16
JP2017070291A (ja) 2017-04-13
US12241098B2 (en) 2025-03-04
US20230029327A1 (en) 2023-01-26
KR102344985B1 (ko) 2021-12-31
CY1119519T1 (el) 2018-03-07
BR112012000784A2 (pt) 2020-08-11
US20120108792A1 (en) 2012-05-03
US11525130B2 (en) 2022-12-13
AU2010273601A1 (en) 2012-02-02
CA2767760C (en) 2018-12-04
US8357541B2 (en) 2013-01-22
US11203748B2 (en) 2021-12-21
HK1247629A1 (en) 2018-09-28
JP2021193103A (ja) 2021-12-23

Similar Documents

Publication Publication Date Title
MX2020009978A (es) Proceso y sistema para obtener neurotoxina botulinica.
CL2013001107A1 (es) Polipeptido derivado de la il-2 con actividad agonista; proteina de fusion que lo comprende; composicion farmaceutica que lo comprende; y su uso para tratar cancer y enfermedades infecciosas cronicas.
CO6650338A2 (es) Antígenos de tuberculosis modificados
BR112013003361A2 (pt) anticorpo, polinucleotídeo e polipeptídeo isolado, composição, vetor, célual hospedeira, método de produção de um anticorpo, conjugado de anticorpo, formulação farmacêutica, uso do anticorpo, métodos de tratamento, de indução e de diagnóstico de doença em um indivíduo
MX387280B (es) Sistema para la producción dirigida de una proteína terapéutica dentro de una célula objetivo y uso del sistema.
BR112015001592A8 (pt) análise de imagem e medidas de amostras biológicas
PH12016500239A1 (en) Antibodies to plasminogen activator inhibitor-1 (pai-1) and uses thereof
AR089752A1 (es) Anticuerpos anti-lrp5 y metodos de uso
BR112012004823A8 (pt) Anticorpo ou fragmento de ligação de antígeno do mesmo, uso de um anticorpo ou um fragmento de ligação de antígeno do mesmo, e composição farmacêutica
BR112013021134A2 (pt) moduladores e métodos de uso
BR112013005116A2 (pt) moduladores e métodos de uso
BR112013014119A8 (pt) Novos moduladores e métodos de uso
AR091098A1 (es) ANTICUERPOS E INMUNOCONJUGADOS CONTRA Ly6E Y METODOS DE USO
MX379312B (es) Anticuerpos especificos para fcrn.
CL2014003322A1 (es) Proteínas de fusión que comprenden una molécula de inmunoglobulina y dos moléculas de interleuquina-2 (il-2); polinucleótido que la codifica; vector; célula huésped; método de producción; composición farmacéutica; y uso para tratar una enfermedad autoinmunológica.
CL2007001488A1 (es) Anticuerpo humano o humanizado anti-integrina alfa5beta1; acido nucleico que lo codifica; vector y celula huesped que lo comprenden; procedimiento de produccion; composicion farmaceutica que lo comprende; y su uso para prevenir o tratar trastornos asociados con la integrina.
BR112012009227A2 (pt) métodos e sistemas para purificar neurotoxina botulínica não complexada
CL2015003801A1 (es) Formulaciones de anticuerpos y metodos
MX392642B (es) Seleccion y desarrollo integrados simultaneos del desempeño y la expresion de proteinas/anticuerpos en hospederos de produccion.
BR112013005145A2 (pt) anticorpos anti-cxcl13 e métodos para seu uso
BR112019004459A2 (pt) métodos para purificar anticorpos
MX2016000794A (es) Composiciones farmaceuticas de pancreatina de potencia alta.
CL2012001143A1 (es) Anticuerpo anti-fractalkina (anti-fkn); composicion farmaceutica que comprende dicho anticuerpo anti-fkn; acido nucleico; vector; celula huesped; uso del anticuerpo anti-fkn para tratar trastornos inflamatorios.
CL2011001904A1 (es) Formulacion farmaceutica que comprende celulas madres mesenquimales vivas suspendidas en un vehiculo farmaceuticamente aceptable, sistema de aplicacion topica en aerosol que las comprende; y su uso para tratar heridas.
CL2011001887A1 (es) Construcciones de proteinas quimericas que poseen propiedades anticoagulantes y tromboliticas; secuencia de acido nucleico que las codifica; vector; celula huesped; metodo de preparacion; formulacion farmaceutica que las comprende; y su uso para inhibir la trombina.